01 Increasing Adoption of High-sensitivity Molecular Detection Technologies The residual DNA testing market is witnessing a shift toward advanced analytical methods that provide higher sensitivity and accuracy in detecting trace host-cell DNA contamination in biologics and gene therapies. Manufacturers are increasingly adopting next-generation sequencing and digital PCR-based approaches to improve quality control, reduce testing limitations, and support regulatory compliance. For example, companies such as QIAGEN and Thermo Fisher Scientific are expanding molecular testing solutions that enable precise nucleic acid quantification for biopharmaceutical applications.
02 Growing Integration of Automated Testing Platforms in Biopharmaceutical Quality Control The residual DNA testing market is moving toward automated and standardized testing workflows as biopharmaceutical manufacturers seek faster turnaround times and improved laboratory efficiency. Automated sample preparation, data analysis, and integrated analytical platforms are reducing manual intervention while improving consistency across testing processes. For example, Bio-Rad Laboratories’ digital PCR platforms support sensitive DNA quantification workflows used in complex biological testing applications, helping laboratories enhance accuracy and operational efficiency.
01 The residual DNA testing market forecasts continued investment activity driven by the growing development of biologics, cell and gene therapies, and mRNA-based products requiring stringent quality control and regulatory compliance. Companies are expected to increase investments in advanced analytical platforms, automation, and high-sensitivity DNA quantification technologies to improve testing accuracy, throughput, and manufacturing efficiency.
02 Key Investment and Fundin Activities in Residual DNA Testing Market I Company Investment/Funding (USD) Details One Biosciences ~USD 17.5 Million (Series A) In July 2025, One Biosciences secured approximately USD 17.5 million to accelerate development of its single-cell analytical platform and expand partnerships with pharmaceutical and biotechnology companies for advanced molecular characterization and quality assessment. Portal Biotech USD 35 Million (Series A) InJune 2025, Portal Biotech raised USD 35 to commercialize its nanopore-based protein characterization platform, expand R&D capabilities, and deepen collaborations with pharmaceutical and biotechnology companies, supporting advanced analytical technologies used in biologics quality control.
01 Growing Adoption of Cell & Gene Therapies and Increasing Shift toward Continuous Bioprocessing Drives Market The expansion of cell and gene therapy manufacturing increases the need for highly sensitive residual DNA testing methods to detect trace genetic impurities from production systems. These therapies involve complex biological processes that require strict monitoring of host cell DNA contamination before clinical use. For example, the FDA approved five cell and gene therapy products in 2025, including therapies such as ITVISMA from Novartis Gene Therapies and WASKYRA, highlighting the continued commercialization of advanced therapies that require rigorous impurity testing and quality control. Gene therapy manufacturers use quantitative PCR- and digital PCR-based assays to verify residual DNA clearance during viral vector production. The increasing commercialization of advanced therapies drives demand for specialized testing platforms and improved batch release confidence.The adoption of continuous manufacturing and single-use bioprocessing systems increases the need for frequent and reliable residual DNA monitoring to maintain process consistency. These manufacturing approaches improve efficiency but require enhanced analytical controls to detect impurities introduced during production cycles. For example, biopharmaceutical companies using bioreactors perform residual DNA analysis to validate process performance and product purity. The growing transition toward flexible manufacturing models drives demand for automated and high-throughput residual DNA testing solutions across biologics production facilities.
01 High Cost of Advanced Molecular Testing Platforms and Complex Method Validation Requirements Restrain Market Expansion Residual DNA testing requires sophisticated analytical platforms such as digital PCR, next-generation sequencing systems, and highly validated reference standards, which involve significant capital and operational costs. Smaller biopharmaceutical manufacturers and contract testing laboratories may face challenges in investing in these advanced technologies due to high equipment costs, assay development expenses, and maintenance requirements. For example, implementation of digital PCR workflows requires specialized instruments, trained personnel, and validated protocols, limiting adoption among resource-constrained laboratories.Residual DNA testing methods require extensive validation to demonstrate accuracy, sensitivity, specificity, and compliance with regulatory expectations across different biologics manufacturing processes. Variations in host-cell systems, production platforms, and assay requirements make standardization challenging for manufacturers. For example, residual DNA testing protocols for CHO cell-derived monoclonal antibodies may require different validation approaches compared with viral vector-based gene therapies. This complexity increases development timelines and testing costs, slowing broader adoption of advanced residual DNA testing solutions.
01 Adoption of Residual DNA Testing for RNA Therapeutics Manufacturing and Development of Platform Specific Residual DNA Assays Offer Growth Opportunities to Market Players The rapid commercialization of mRNA vaccines and RNA-based therapeutics is creating opportunities to develop residual DNA assays specifically for plasmid DNA clearance during in vitro transcription manufacturing. Unlike conventional biologics, RNA therapeutics require monitoring of residual template DNA at extremely low concentrations before product release. As more companies establish large-scale mRNA manufacturing facilities, demand for validated, high-sensitivity residual DNA testing kits designed for RNA production workflows is expected to increase significantly.The growing use of alternative expression systems such as HEK293, Sf9 insect cells, Vero cells, and yeast is creating demand for customized residual DNA assays tailored to individual manufacturing platforms. Most commercial assays have traditionally focused on CHO- and E. coli-derived products, leaving an unmet need for validated platform-specific solutions. Companies that develop standardized assays and certified reference materials for emerging host-cell systems can gain a competitive advantage as biologics manufacturing becomes increasingly diversified.
01 Absence of Universal Assays and Difficulty in Establishing Matrix Specific Reference Standards Challenges Market Growth A major challenge for the residual DNA testing market is the absence of universally applicable assays that perform consistently across different host cell expression systems and advanced therapy manufacturing platforms. Residual DNA characteristics vary significantly between CHO cells, HEK293 cells, Vero cells, E. coli, yeast, and insect cells, requiring platform-specific assay design and validation. This increases assay development time, regulatory documentation, and testing costs, limiting workflow standardization for manufacturers operating multiple production platforms.Another challenge for the residual DNA testing market is the lack of universally accepted matrix-specific reference standards for different biological products and manufacturing processes. Variations in formulations, excipients, purification methods, and host-cell expression systems can influence DNA extraction efficiency and assay performance, making it difficult to achieve comparable results across laboratories.
April 2026 Roche announced an agreement to acquire SAGA Diagnostics for up to USD 595 million, strengthening its ultra-sensitive DNA detection portfolio through digital PCR and sequencing technologies applicable to high-sensitivity DNA analysis.
September 2025 Bio-Rad Laboratories launched the Vericheck ddPCR Residual DNA Quantification Kit, designed for highly sensitive quantification of residual host-cell DNA in biopharmaceutical products, expanding its digital PCR portfolio for biologics quality control applications.